Pérez Vicente Estrada, Sánchez-Parra Clara, Serrano Villar Sergio
Hospital Clínico San Carlos, Madrid, España.
Enferm Infecc Microbiol Clin. 2009 Dec;27 Suppl 2:27-31. doi: 10.1016/S0213-005X(09)73216-1.
Etravirine (ETR) belongs to the family of non-nucleoside analogue reverse transcriptase inhibitors (NNRTIs), with antiviral activity in patients with resistance to first-generation NNRTIs. The drug interactions caused by ETR are due to its dual effect on the CYP450 system. ETR acts as an inducer of CYP3A4 and inhibitor of CYP2C9 and CYP2C19. This drug shows few clinically significant drug interactions, the most important of which involve the unboosted protease inhibitors, the NNRTIs efavirenz and nevirapine, full-dose ritonavir and tipranavir/ritonavir. Interaction with fosamprenavir/ritonavir is not clinically significant, although their plasma levels vary slightly when used in combination with ETR. ETR shows no interactions with darunavir/ritonavir.
依曲韦林(ETR)属于非核苷类逆转录酶抑制剂(NNRTIs)家族,对第一代NNRTIs耐药的患者具有抗病毒活性。ETR引起的药物相互作用是由于其对细胞色素P450(CYP450)系统的双重作用。ETR是CYP3A4的诱导剂,也是CYP2C9和CYP2C19的抑制剂。该药物显示出很少有临床显著的药物相互作用,其中最重要的涉及未增强的蛋白酶抑制剂、NNRTIs依非韦伦和奈韦拉平、全剂量利托那韦以及替拉那韦/利托那韦。与福沙普那韦/利托那韦的相互作用在临床上不显著,尽管它们与ETR联合使用时血浆水平略有变化。ETR与达芦那韦/利托那韦无相互作用。